News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
321,416 Results
Type
Article (19070)
Company Profile (31)
Press Release (302315)
Multimedia
Podcasts (37)
Webinars (7)
Section
Business (82640)
Career Advice (218)
Deals (13574)
Drug Delivery (35)
Drug Development (77002)
Employer Resources (19)
FDA (8217)
Job Trends (6303)
News (174824)
Policy (12638)
Tag
Academia (794)
Accelerated approval (24)
Adcomms (22)
Allergies (99)
Alliances (22338)
ALS (144)
Alzheimer's disease (1409)
Antibody-drug conjugate (ADC) (261)
Approvals (8406)
Artificial intelligence (271)
Autoimmune disease (121)
Automation (16)
Bankruptcy (99)
Best Places to Work (5384)
BIOSECURE Act (3)
Biosimilars (65)
Biotechnology (19)
Bladder cancer (149)
Brain cancer (50)
Breast cancer (544)
Cancer (4046)
Cardiovascular disease (290)
Career advice (195)
Career pathing (3)
CAR-T (211)
CDC (3)
Celiac Disease (2)
Cell therapy (483)
Cervical cancer (26)
Clinical research (70390)
Collaboration (911)
Company closure (4)
Compensation (353)
Complete response letters (46)
COVID-19 (1914)
CRISPR (43)
C-suite (509)
Cystic fibrosis (107)
Data (5115)
Decentralized trials (2)
Denatured (1)
Depression (107)
Diabetes (310)
Diagnostics (6263)
Digital health (27)
Diversity (1)
Diversity, equity & inclusion (8)
Drug discovery (110)
Drug pricing (31)
Drug shortages (5)
Duchenne muscular dystrophy (160)
Earnings (37463)
Editorial (15)
Employer branding (3)
Employer resources (19)
Events (47694)
Executive appointments (534)
FDA (10279)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (15)
Funding (853)
Gene editing (93)
Generative AI (23)
Gene therapy (362)
GLP-1 (736)
Government (1735)
Grass and pollen (4)
Guidances (234)
Healthcare (6818)
HIV (44)
Huntington's disease (40)
IgA nephropathy (75)
Immunology and inflammation (230)
Immuno-oncology (54)
Indications (83)
Infectious disease (2106)
Inflammatory bowel disease (136)
Inflation Reduction Act (2)
Influenza (85)
Intellectual property (142)
Interviews (43)
IPO (6583)
IRA (6)
Job creations (1195)
Job search strategy (165)
JPM (30)
Kidney cancer (16)
Labor market (7)
Layoffs (312)
Leadership (4)
Legal (1157)
Liver cancer (75)
Longevity (9)
Lung cancer (601)
Lymphoma (348)
Machine learning (16)
Management (3)
Manufacturing (338)
MASH (155)
Medical device (3510)
Medtech (3530)
Mergers & acquisitions (7521)
Metabolic disorders (917)
Multiple sclerosis (146)
NASH (20)
Neurodegenerative disease (287)
Neuropsychiatric disorders (84)
Neuroscience (2403)
Neurotech (1)
NextGen: Class of 2026 (1709)
Non-profit (903)
Now hiring (3)
Obesity (441)
Opinion (95)
Ovarian cancer (150)
Pain (133)
Pancreatic cancer (190)
Parkinson's disease (233)
Partnered (11)
Patents (231)
Patient recruitment (424)
Peanut (51)
People (23226)
Pharmaceutical (8)
Pharmacy benefit managers (4)
Phase 1 (22039)
Phase 2 (31847)
Phase 3 (23781)
Pipeline (3868)
Policy (53)
Postmarket research (1077)
Preclinical (4658)
Press Release (26)
Prostate cancer (204)
Psychedelics (49)
Radiopharmaceuticals (232)
Rare diseases (627)
Real estate (1953)
Recruiting (7)
Regulatory (12603)
Reports (16)
Research institute (982)
Resumes & cover letters (33)
Rett syndrome (24)
RNA editing (11)
RSV (55)
Schizophrenia (135)
Series A (144)
Series B (125)
Service/supplier (1)
Sickle cell disease (51)
Special edition (8)
Spinal muscular atrophy (125)
Sponsored (26)
Startups (1495)
Stomach cancer (16)
Supply chain (28)
Tariffs (21)
The Weekly (36)
Vaccines (628)
Venture capital (56)
Weight loss (284)
Women's health (45)
Date
Today (77)
Last 7 days (358)
Last 30 days (1243)
Last 365 days (18345)
2026 (1913)
2025 (18441)
2024 (20361)
2023 (22834)
2022 (28539)
2021 (28869)
2020 (25374)
2019 (17571)
2018 (13584)
2017 (16322)
2016 (14619)
2015 (17221)
2014 (12439)
2013 (9737)
2012 (10261)
2011 (10826)
2010 (9797)
Location
Africa (244)
Alabama (41)
Alaska (2)
Arizona (120)
Arkansas (5)
Asia (21099)
Australia (4053)
California (6741)
Canada (1697)
China (785)
Colorado (242)
Connecticut (309)
Delaware (181)
Europe (49785)
Florida (838)
Georgia (218)
Hawaii (1)
Idaho (14)
Illinois (409)
India (31)
Indiana (277)
Iowa (16)
Japan (306)
Kansas (57)
Kentucky (26)
Louisiana (10)
Maine (27)
Maryland (725)
Massachusetts (4540)
Michigan (153)
Minnesota (243)
Mississippi (3)
Missouri (69)
Montana (22)
Nebraska (14)
Nevada (68)
New Hampshire (32)
New Jersey (1813)
New Mexico (22)
New York (1881)
North Carolina (850)
North Dakota (7)
Northern California (3380)
Ohio (153)
Oklahoma (11)
Oregon (23)
Pennsylvania (1217)
Puerto Rico (14)
Rhode Island (9)
South America (311)
South Carolina (13)
Southern California (2658)
Tennessee (82)
Texas (1027)
United States (22756)
Utah (227)
Virginia (132)
Washington D.C. (27)
Washington State (522)
West Virginia (1)
Wisconsin (81)
Wyoming (2)
321,416 Results for "phase diagnostics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension
January 7, 2026
·
4 min read
Press Releases
Pentixapharm Announces Peer-Reviewed Phase 2 Data Back Use of PENTIXAFOR as a Superior Non-invasive PET-Diagnostic for Primary Aldosteronism
February 5, 2026
·
6 min read
Obesity
Kailera, Hengrui Push Oral GLP-1/GIP Pill to Phase 3 After Clearing Mid-Stage China Study
Kailera will launch a global Phase 2 study of ribupatide this year, while Hengrui will push the asset into Phase 3 in China.
February 10, 2026
·
1 min read
·
Tristan Manalac
Rare disease
Sanofi Rare Disease Drug Scores a Hit and a Miss in Phase III Tests
Sanofi will take venglustat to regulators for Gaucher disease but an application for Fabry disease is less clear after the failure of a Phase III trial.
February 2, 2026
·
1 min read
·
Annalee Armstrong
Immunology and inflammation
Priovant Plots Path to Phase 3 as Brepocitinib Clears Mid-Stage Skin Disease Study
According to Priovant, the Phase 2 BEACON study is the first industry-sponsored placebo-controlled trial in cutaneous sarcoidosis to deliver positive data.
February 6, 2026
·
2 min read
·
Tristan Manalac
GLP-1
Roche’s 22% Weight Loss Benefit Seals GLP-1’s Phase III Plans, Boosts Zealand Combo
Roche said the Phase II results help build the case for advancing CT-388 into late-stage testing, which is set to get underway this quarter.
January 27, 2026
·
2 min read
·
Annalee Armstrong
Press Releases
Burst Diagnostics and FemmeLoop Secure NIH Funding to Advance At-Home Diagnostics for Perimenopause
NIH Phase I SBIR grant will support development of a low-cost, multiplexed, at-home hormone test to transform menopause care.
October 30, 2025
·
1 min read
Alzheimer’s disease
BMS Delays Cobenfy Alzheimer’s Psychosis Data After ‘Irregularities’ in Phase III Study
Analysts had noted “unease” from investors regarding the state of the Phase III ADEPT-2 trial, with BMS at one point telling Leerink Partners that the reopening of enrollment would be a “significant development.”
December 3, 2025
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Bayer Sets Up Redemption Arc for Anticoagulant With ‘Surprisingly Positive’ Phase III Data
Asundexian’s Phase III win could also bode well for Bristol Myers Squibb, which is also developing a Factor XIa inhibitor called milvexian for stroke prevention, analysts said.
November 24, 2025
·
2 min read
·
Tristan Manalac
Neuroscience
Alkermes Pushes Narcolepsy Program to Phase III With ‘Highly Competitive’ Mid-Stage Data
Alixorexton’s Phase II performance sets it up for late-stage success, according to analysts at Truist Securities. Alkermes expects to launch a global late-stage program early next year for narcolepsy type 2.
November 13, 2025
·
2 min read
·
Tristan Manalac
1 of 32,142
Next
